172 related articles for article (PubMed ID: 24138841)
1. Molecular and protein markers for clinical decision making in breast cancer: today and tomorrow.
Harbeck N; Sotlar K; Wuerstlein R; Doisneau-Sixou S
Cancer Treat Rev; 2014 Apr; 40(3):434-44. PubMed ID: 24138841
[TBL] [Abstract][Full Text] [Related]
2. Is gene array testing to be considered routine now?
Paik S
Breast; 2011 Oct; 20 Suppl 3():S87-91. PubMed ID: 22015300
[TBL] [Abstract][Full Text] [Related]
3. Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays.
Albain KS; Paik S; van't Veer L
Breast; 2009 Oct; 18 Suppl 3():S141-5. PubMed ID: 19914534
[TBL] [Abstract][Full Text] [Related]
4. Multigene classifiers, prognostic factors, and predictors of breast cancer clinical outcome.
Ross JS
Adv Anat Pathol; 2009 Jul; 16(4):204-15. PubMed ID: 19546609
[TBL] [Abstract][Full Text] [Related]
5. Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients.
Harbeck N; Schmitt M; Meisner C; Friedel C; Untch M; Schmidt M; Sweep CG; Lisboa BW; Lux MP; Beck T; Hasmüller S; Kiechle M; Jänicke F; Thomssen C;
Eur J Cancer; 2013 May; 49(8):1825-35. PubMed ID: 23490655
[TBL] [Abstract][Full Text] [Related]
6. Molecular profiling assays in breast cancer: are we ready for prime time?
Gökmen-Polar Y; Badve S
Oncology (Williston Park); 2012 Apr; 26(4):350-7, 361. PubMed ID: 22655528
[TBL] [Abstract][Full Text] [Related]
7. Using multigene tests to select treatment for early-stage breast cancer.
Goncalves R; Bose R
J Natl Compr Canc Netw; 2013 Feb; 11(2):174-82; quiz 182. PubMed ID: 23411384
[TBL] [Abstract][Full Text] [Related]
8. Commercialized multigene predictors of clinical outcome for breast cancer.
Ross JS; Hatzis C; Symmans WF; Pusztai L; Hortobágyi GN
Oncologist; 2008 May; 13(5):477-93. PubMed ID: 18515733
[TBL] [Abstract][Full Text] [Related]
9. [A Review Multigene Assays for Clinical Utility in Breast Cancer].
Araki K; Ito Y
Gan To Kagaku Ryoho; 2016 Nov; 43(11):1332-1340. PubMed ID: 27899774
[TBL] [Abstract][Full Text] [Related]
10. Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-I: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer.
Harbeck N; Kates RE; Gauger K; Willems A; Kiechle M; Magdolen V; Schmitt M
Thromb Haemost; 2004 Mar; 91(3):450-6. PubMed ID: 14983219
[TBL] [Abstract][Full Text] [Related]
11. Critical review of microarray-based prognostic tests and trials in breast cancer.
Koscielny S
Curr Opin Obstet Gynecol; 2008 Feb; 20(1):47-50. PubMed ID: 18197005
[TBL] [Abstract][Full Text] [Related]
12. A new look at node-negative breast cancer.
Harbeck N; Thomssen C
Oncologist; 2010; 15 Suppl 5():29-38. PubMed ID: 21138953
[TBL] [Abstract][Full Text] [Related]
13. Health-related quality of life in early breast cancer.
Groenvold M
Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
[TBL] [Abstract][Full Text] [Related]
14. Multigene Assays for Classification, Prognosis, and Prediction in Breast Cancer: a Critical Review on the Background and Clinical Utility.
Sinn P; Aulmann S; Wirtz R; Schott S; Marmé F; Varga Z; Lebeau A; Kreipe H; Schneeweiss A
Geburtshilfe Frauenheilkd; 2013 Sep; 73(9):932-940. PubMed ID: 24771945
[TBL] [Abstract][Full Text] [Related]
15. Clinical experience of using Oncotype DX as an additional treatment decision tool in early breast cancer - a retrospective analysis from 5 Greek institutions.
Markopoulos C; Xepapadakis G; Venizelos V; Tsiftsoglou A; Misitzis J; Panoussis D; Antonopoulou Z; Stathoulopoulou M; Zobolas V; Gogas H
Eur J Surg Oncol; 2012 May; 38(5):413-9. PubMed ID: 22425282
[TBL] [Abstract][Full Text] [Related]
16. Decision making in surgical treatment of chronic low back pain: the performance of prognostic tests to select patients for lumbar spinal fusion.
Willems P
Acta Orthop Suppl; 2013 Feb; 84(349):1-35. PubMed ID: 23427903
[TBL] [Abstract][Full Text] [Related]
17. Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer?
Asad J; Jacobson AF; Estabrook A; Smith SR; Boolbol SK; Feldman SM; Osborne MP; Boachie-Adjei K; Twardzik W; Tartter PI
Am J Surg; 2008 Oct; 196(4):527-9. PubMed ID: 18809056
[TBL] [Abstract][Full Text] [Related]
18. Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting.
Blohmer JU; Rezai M; Kümmel S; Kühn T; Warm M; Friedrichs K; Benkow A; Valentine WJ; Eiermann W
J Med Econ; 2013; 16(1):30-40. PubMed ID: 22966753
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of international treatment guidelines and prognostic tests for the treatment of early breast cancer.
Muñoz M; Estévez LG; Alvarez I; Fernández Y; Margelí M; Tusquets I; Seguí MA; Lluch A
Cancer Treat Rev; 2008 Dec; 34(8):701-9. PubMed ID: 18922644
[TBL] [Abstract][Full Text] [Related]
20. Use of standard markers and incorporation of molecular markers into breast cancer therapy: Consensus recommendations from an International Expert Panel.
Kaufmann M; Pusztai L;
Cancer; 2011 Apr; 117(8):1575-82. PubMed ID: 21472705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
